Cart
sales@molnova.com
DMH4
CAS No. 515880-75-8
DMH4( —— )
Catalog No. M33846 CAS No. 515880-75-8
DMH4 is a potent and selective inhibitor of VEGFR2 with an IC50 of 0.16 μM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 71 | In Stock |
|
| 10MG | 102 | In Stock |
|
| 25MG | 168 | In Stock |
|
| 50MG | 244 | In Stock |
|
| 100MG | 360 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDMH4
-
NoteResearch use only, not for human use.
-
Brief DescriptionDMH4 is a potent and selective inhibitor of VEGFR2 with an IC50 of 0.16 μM.
-
DescriptionDMH4 is a potent and selective inhibitor of VEGFR2 with an IC50 of 0.16 μM.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetVEGFR
-
RecptorVEGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number515880-75-8
-
Formula Weight400.47
-
Molecular FormulaC24H24N4O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(CN1CCOCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Hao J, et al. In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors. ACS Chem Biol. 2010 Feb 19;5(2):245-53.??
molnova catalog
related products
-
Motesanib diphosphat...
A potent, orally bioavailable, multikinase inhibitor inhibitor of VEGFR1/2/3, PDGFR and c-Kit with IC50 of 2-6 nM, 84 nM and 8 nM, respectively.
-
PAN-90806
PAN-90806 (CP-547632, CP547632) is a highly potent, ATP-competitive, orally active VEGFR-2 inhibitor that blocks VEGFR-2 kinase autophosphorylation (IC50=11 nM) and VEGF-induced VEGFR-2 phosphorylation (IC50=5 nM).
-
8-O-Acetylshanzhisid...
8-O-Acetylshanzhiside methylester has potential against cerebral ischemic injury, and its protective effect on oxygen-glucose deprivation-induced injury might be due to the suppression of intracellular Ca2+ elevation and caspase-3 activity.
